Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, progressive neurodegenerative disease, in individuals aged 16 years and above. The ...

The positive data from a phase 2 trial of omaveloxolone in neurodegenerative disorder Friedreich’s ataxia prompted a 34% increase in Reata’s share price after-hours, which added to earlier ...

At this point, there are several therapies which are coming along, a large trial called the ExRx trial, which included the nutraceutical, nicotinamide riboside has finished. The data are not yet ...